The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โABBVโ.
According to AbbVie's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 4.48398. At the end of 2022 the company had a P/S ratio of 4.10.
Year | P/S ratio | Change |
---|---|---|
2022 | 4.10 | -3.65% |
2021 | 4.26 | 3.14% |
2020 | 4.13 | 4.92% |
2019 | 3.94 | -5.43% |
2018 | 4.16 | -23.93% |
2017 | 5.47 | 37.85% |
2016 | 3.97 | -4.86% |
2015 | 4.17 | -20.04% |
2014 | 5.22 | 16.95% |
2013 | 4.46 | 51.93% |
2012 | 2.94 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
![]() Pfizer PFE | 2.48 | -44.78% | ๐บ๐ธ USA |
![]() Eli Lilly LLY | 11.1 | 148.27% | ๐บ๐ธ USA |
![]() Amgen AMGN | 4.99 | 11.36% | ๐บ๐ธ USA |
![]() Biogen BIIB | 4.05 | -9.64% | ๐บ๐ธ USA |
![]() Gilead Sciences GILD | 3.88 | -13.41% | ๐บ๐ธ USA |
![]() Bristol-Myers Squibb BMY | 3.24 | -27.74% | ๐บ๐ธ USA |
![]() AstraZeneca AZN | 4.37 | -2.56% | ๐ฌ๐ง UK |
![]() GlaxoSmithKline GSK | 1.70 | -62.20% | ๐ฌ๐ง UK |
![]() Neurocrine Biosciences
NBIX | 7.63 | 70.16% | ๐บ๐ธ USA |